Fig. 6

DAG homes to the brain in mouse models of neuroinflammation. a DAG targets brain in mouse model of glioblastoma. FAM-DAG was intravenously injected to mice bearing an angiogenic glioblastoma derived from a patient (P13), and allowed to circulate for 30 min, after which the mice were perfused, the tumors were fixed, sectioned and stained for FAM (green), and GFAP (red). Scale bar, 40 µm. b DAG homes to acute brain injury in mice. FAM-DAG was injected intravenously in mice with penetrating brain injury, processed as in panel a. Representative immunofluorescence images of brain sections from the injury area stained for FAM (green), and CD31 (red; left and middle panels) or GFAP (red; right panel) show stellate-shaped cells positive for DAG (see arrow). Scale bar, 40 µm. c–e DAG homes to the brain in a Parkinson’s disease mouse model. FAM-labeled DAG or control peptide was intravenously injected to Parkinson’s disease mice (mTHY-1-α-synuclein model, 1-year old) and processed as in panel a. c Brain sections were stained for FAM (green) and counterstained with DAPI Scale bar, 100 μm. Inset shows a typical worm-like structure targeted by DAG in the cortex. Scale bar, 20 μm. d Fluorescence signal from FAM in panel c was quantified using ImageJ. e Brain sections from DAG-injected mice were stained for FAM (green) and GFAP (red). DAG signal associates with activated astrocytes. Scale bar, 40 µm. *P < 0.05